Calreticulin and type I interferon: An unsuspected connection

Lorenzo Galluzzi; Guido Guido Kroemer

doi:10.1080/2162402x.2017.1288334

Related publications

Article2014

Novel immune checkpoint blocker approved for the treatment of advanced melanoma

Lorenzo Galluzzi, Guido Guido Kroemer, Alexander Eggermont

Article2010

Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia

Mathieu Wémeau, Oliver Kepp, Antoine Tesnière, Theocharis Panaretakis, Caroline Flament, Stéphane de Botton, Laurence Zitvogel, Guido Guido Kroemer, Nathalie Chaput

Article2025

BATF2 is a glutamine-responsive tumor suppressor essential for type I interferon-dependent anti-tumor immunity 2283

Yu L. Lei, Wang Gong, Hülya F. Taner, Yuesong Wu, Qiang Hu, Christopher R. Donnelly, HE Yu-min, Zhenhua Zhai, Zackary R. Fitzsimonds, Jiaqian Li, Deepak Nagrath, Gregory T. Wolf, Haitao Wen, Akira Shizuo, Yuying Xie, James J. Moon

Article2010

Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

Deepa Rajagopal, Carine Paturel, Yannis Morel, Satoshi Uematsu, Akira Shizuo, Sandra S. Diebold

Blood

Article2011

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals <i>via</i> VEGF receptor Type 2

Apostolos C Ziogas, Nikos G. Gavalas, Marinos Tsiatas, Ourania Tsitsilonis, Ekaterini Politi, Evangelos Terpos, Alexandros Rodolakis, George Vlahos, Nikolaos Thomakos, Dimitrios Haidopoulos, A. Antsaklis, Meletios A Dimopoulos, Aristotle Bamias